Alnylam Pharmaceuticals (ALNY) Profit After Tax (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Profit After Tax data on file, last reported at $164.5 million in Q2 2026.

• Quarterly Profit After Tax rose 327.74% year-over-year to $164.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $743.0 million (up 351.42% YoY) and the FY2025 annual result came in at $328.2 million, up 213.44% from the prior year.
• Profit After Tax declined to $164.5 million in Q2 2026, from $206.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $259.3 million in Q3 2025 to a low of -$407.5 million in Q3 2022.
• A 5-year average of -$66.9 million and a median of -$82.8 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2025 — Profit After Tax sank 327.66% — and 2026, when it soared 1228.66%.
• Tracing ALNY's Profit After Tax over 5 years: stood at -$208.4 million in 2022, then surged by 33.83% to -$137.9 million in 2023, then soared by 32.22% to -$93.5 million in 2024, then soared by 221.15% to $113.2 million in 2025, then surged by 45.29% to $164.5 million in 2026.
• The last three Profit After Tax figures came in at $164.5 million (Q2 2026), $206.0 million (Q1 2026), and $113.2 million (Q4 2025), per Business Quant data.